International Speaker_10thNEW

Jamal is a dynamic business leader with 24+ years of high caliber experience in management consulting, healthcare, regulatory affairs and compliance, healthcare IT, medical devices, and business management in the Middle East and USA. He has worked in several geographies, including KSA, UAE, Bahrain, Jordan, and USA. He is intimately familiar with GCC culture, future outlook, and opportunities for development. He has worked across several consulting competencies (Performance Improvement, risk, IT Advisory), all with successful results.

He has managed engagements in several sectors (i.e. P&U, Telco, AAIC, Healthcare), for government and private clients. He worked in the industry and has wealth of knowledge with respect to clients’ needs. In terms of healthcare strategy and reform, he has helped clients articulate and understand their strategies at the department, entity and systems levels.

Jamal was columnist for Arab Health Magazine; “Expert Opinion” and a speaker at the Life Sciences Foresight series hosted by Dubai Science Park.
Jamal has in depth knowledge is several quality management systems, including ISO, CE-MARK, TUV, etc. and successfully obtained compliance certifications, in line with these systems, for several entities

Dr. Ayach is Senior Director with GE Healthcare & Partners, EGM. He specializes in both corporate and government sector to help address key strategic and operational challenges related to long term strategy design and development, leading and managing transformational projects, market feasibility, entrepreneurship and value development. He brings over 17 years of consulting experience across Europe and the Middle East, in which he worked with top executives and decision makers where he provided expertise in business growth strategies, business incubation and internationalization, Healthcare performance optimization, strategy design, value based Healthcare, smart health system engineering and IT integration, PPP’s, Medical tourism and overseas treatment strategies, business and operation modelling, market access and greenfield hospital planning and implementation.

He received the European Executive Award for enterprise engineering and consulting in business internationalization strategies for small and medium enterprises, by the National Center of Research, Italy. He has various working papers, book chapters and international publications on topics such as efficiency modelling and innovation in the Healthcare sector, and he is member at the European Decision Science Institute.

Ali has the following educational qualifications:

• Post Doctorate in Decision Science
• Ph.D. in Management and Enterprise Engineering University of Rome 2, Italy & Harvard University, USA
• ECE, Leadership and Conflict Resolution, Harvard University, USA
• MBA , Enterprise Engineering , Rome 2 , Italy
• Master in Bio-Robotics Engineering , Rome La Sapienza , Italy
• B.Eng. in Mechanical Engineering, Rome La Sapienza, Italy

Prior to GE Healthcare & Partners , Ali worked at Philips Consulting where he supported in developing the Healthcare practice and led successfully multiple organizational engagements in the Middle East. He supported clients including Healthcare regulators and Operators, and research centers, and fulfilled variety of consulting roles in which he led large transformation programs such as system wide outpatients and surgical transformation, performance and productivity improvement, data analytics, and IT system integration architecture review , including transformation orchestration, capacity planning, workflow optimization and clinical service modeling, and launch of new medical facility. Prior to Philips Consulting, he has served in senior advisory roles with Dubai Government, including Health Authorities.. Ali has also worked with Accenture based in Europe on a variety of strategic and operational projects in healthcare including: M&A, health technology assessment, process re-engineering, and decision analysis with a focus in policy implementation, change management and integration. He also has experience working as a researcher and assistant professor at the University of Rome, Faculty of Management Engineering.

Walter (Wally) Klemp is the Chairman and CEO of Moleculin Biotech, Inc., a Nasdaq-listed (Nasdaq: MBRX) drug development company based in Houston, Texas.

Mr. Klemp helped facilitate an initiative similar to Saudi Arabia’s Vision 2030 in the country of Poland. This was called “Vision 2020,” and it’ objective was to help diversify Poland’s economy by establishing Poland as a hub for new technology, with an emphasis on biotechnology, throughout Eastern Europe. Specifically, Moleculin, which had been developing technologies discovered at MD Anderson Cancer Center (the world’s largest cancer research center), sublicensed cutting edge cancer drug technologies to development companies in Poland (including rights to surrounding territories) in exchange for access to grant funding intended for their Vision 2020. This led directly to the expansion of clinical trial activity in Poland.

As a comparison, Saudi Arabia and Poland are both similar in population, have well-established medical infrastructures and are geographically positioned to provide leadership throughout their respective regions. In contrast, however, today there are approximately 4 times as many clinical trials just in the city of Warsaw as there are in the entirety of Saudi Arabia. Mr. Klemp proposes to help Saudi Arabia facilitate its Vision 2030 in much the same way as Poland, through the dramatic expansion of clinical trial activity by jump-starting Saudi Arabia’s access to new technologies through in-licensing activities.

Mr. Klemp is the Founder and Chairman of two current Nasdaq-listed biotech companies (MBRX, SOLY), one in cancer drug development and one in medical devices. With 17 years in the biotechnology industry, he has been responsible for numerous clinical trials, as well as regulatory approvals of both drugs and devices and out-licenses to EU and Asian drug companies. He has raised over $.75 billion in development stage funding for his companies, including 7 public securities issuances and 4 Nasdaq IPOs. Mr. Klemp’s first company became #1 on the INC 500 List of America’s Fastest Growing Companies, as well as earning the American Marketing Association’s Gold Edison Award. He was invited to serve as an Advisor to the White House Conference on Small Business and has delivered numerous lectures on the development of the biotechnology sectors.

Gjon Mirdita is a Doctor of Dental Medicine by training, with more than 18 years of experience in the Pharmaceutical and Clinical Research industries, fulfilling various roles in Clinical Operations, Regulatory and Start-up and Medical Affairs. He is experienced in leading large international, cross-functional teams and has a passion for providing and accelerating access to new treatments for patients in need.

Sanjeev Gupta graduated from the university of Calicut with a Degree in Electrical Engineering and has a strong background and experience in the implementation of heavily IT driven solutions this brought him to software engineering in 1998, when he joined a Belgian healthcare company.  This led to a close collaboration with IBM”s R&D labs in Rochester, Minnesota and IBM Global Services Belgium.  Thereafter he moved on to work for AIS Systems  (VAtech, Austrian based Steel Technology company – software development in the areas of automating complex regulated research in production environments and planning systems). In 2004 Sanjeev took another step forward by setting up his own IT company, providing consultancy services to pharmaceutical and bio-technology companies in Europe and the US.

Sanjeev has gained a good reputation amongst his peers as a solid developer and in the conceptualization and design of best-in-class software solutions, based on leading-edge technology, today he leads Arisglobals Eclincal solutions team in Europe out of Belguim and is involved in all aspects of CTMS and Eclinical

Ersen Gokser is molecular biologist by education and graduated from Middle East Technical University Biological Sciences, Ankara, Turkey. Ersen is currently working as Senior Manager, Development Operations at Amgen. He pursued a career in pharmaceutical industry and started to work in clinical research area at Eli Lilly & Company in 2003 as a Clinical Research Associate. Ersen took the position of Area Quality Coordinator role for medical department of Lilly Turkey in 2004. After one year, his area of responsibility expanded to cover Romania, Bulgaria, Croatia and Slovenia and he was promoted to the role of Area Quality Consultant in 2007. He was promoted to the role of Clinical Research Manager in 2007 and continued to work for Lilly until 2009. During 2009-2013, he worked as Clinical Operations Manager for Abbott, Business Operations Lead for Pfizer and Clinical Operations Manager at Novo Nordisk before joining Amgen.

He is currently acting as Country Network lead for TransCelerate Inc. in Turkey. He was also an active member of the GCP Committee at Association of Research-Based Pharmaceutical Companies and served as Vice Chairman of the committee for the periods 2009-2010 and 2012-2019.

Dr. Yon Su Kim had his Phd from Seoul University College of Medicine in 1996. Dr. Kim has had long working experience varied in different fields. He started as an Assistant Professor in 1999 and now working as a President and CEO of Seoul National University Hospital. Some of Dr. Kim’s academic activities are General Secretary, Korean Society of Nephrology, Seoul, Korea; Director, Board of External Affairs and Cooperation; Director, Board of Academic Affairs Korean Society of Nephrology, Seoul, Korea; Director, Board of Planning Korean Society of Nephrology, Seoul, Korea and President Korean Society of Nephrology, Seoul, Korea. He is also a member in Korean society of Nephrology, Korean Society of Organ Transplantation, American Society of Nephrology, American Society of Transplantation, International society of Nephrology.

• Expertise Clinical Chemistry / Metabolic Medicine
• Memberships Fellow Royal College of Physicians of Ireland 2004
• Member Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom 2012
• Fellow Royal College of Pathologists 2001 (emeritus 2010)
• Other Relevant Information UK representative on Blood Products Working Party
• UK representative on Committee for Advanced Therapies

• Medical Doctor with specialization in Pharmaceutical Medicine
• 32 years experience in Health Care Industry
• mMBA Wharton/INSEAD
• Former Chief Medical Officer and Innovation/R&D Head for “Emerging Markets” at Sanofi
• Former Global Head Regulatory Affairs CHC at Roche
• Former country medical director for different groups in several European countries

Competencies:

• Expert in Medical Affairs, Emerging Markets, Drug Development( Industrial , Preclinical & Clinical), Innovation, External Partnerships and Management
• From Medical Devices to Pharma (both prescription medicines and Consumer Health Care)
• Across Medical Affairs functions (from Medical to Regulatory passing by Market Access, R&D …) and beyond (Business, Marketing, Innovation )
• Experience both at country level (Belgium, The Netherlands, and Spain) and corporate level (Global and Emerging Markets)

Career Summary:

• Global CMO, AB Science
  • Vice-President & Global Head of Innovation –Value Added Medicines Innovation Centre-Sanofi Global BU General Medicines & Emerging Markets(GEM)
  • Vice-President Emerging Markets Innovation & Search Unit/EMISU-Sanofi Global Ops & R&D
  • VP/ Chief Medical Officer & R&D Head –Sanofi Intercontinental
  • Medical, Clinical and Scientific Affairs Director Sanofi-Aventis Belgium
  • Senior Medical Director-Aventis Spain
  • Medical Director-Aventis Belgium
  • Medical Director-Sanofi-Synthelabo Belgium
  • Director of Clinical Research, Medical and Regulatory Affairs-Synthelabo Belgium
  • Head of International Regulatory Affairs and Rx to OTC Switches Project Director

• Roche Consumer Health World-wide
  • Medical Manager & Business Therapy Area Coordinator( BU Head)-Roche Belgium
  • Director of Medical, Clinical & Regulatory Affairs-Syntex Benelux
  • Scientific & Regulatory Affairs Officer-3M Health Care Belgium
  • Medical practices

Coming Soon